Relevant comorbidities include presence of associated atopic comorbidities or type 2 inflammatory diseases.

Data for any of the following laboratory parameters will be collected as available in routine clinical practice and expressed in the units relevant for the respective parameter: bilirubin, aspartate amino transferase (AST), alanine amino transferase (ALT), gamma glutamyl transferase (gamma GT), alkaline phosphatase, differential blood count, ferritin, erythrocyte sedimentation rate, C-reactive protein.

PGIC is a 7-point scale to assess patient health and determine if there has been an improvement or decline in clinical status. Patients are asked to rate their overall status since the start of the study from "very much improved" to "very much worse". Scores range from 1 to 7, with higher score indicating worse health status.

PCT is a self-administered, simple 5-item tool. A score between 0 and 4 is assigned to every answer option. Subsequently, the scores for all 5 questions are summed up. Accordingly, the minimum and maximum PCT scores are 0 and 20, with higher scores indicating a higher level of disease control.

DLQI is developed to measure dermatology specific Health-Related Quality of Life (HRQoL) in adult participants. It comprises of set of 10 questions assessing the impact of skin disease on participants' HRQoL over the previous week. Responses to each question were assessed on a 4-point Likert scale ranged from 0 (not at all) to 3 (very much). Scores from all 10 questions added up to give total DLQI scores ranged from 0 (not at all) to 30 (very much), higher scores indicated more impact on quality of life.

Sleep-NRS was used to measure sleep intensity. Participants were asked to rate their sleep quality on their past night upon awakening, using a 11-point NRS ranging from 0 to 10, where 0 = worst possible sleep and 10 = best possible sleep. Higher scores indicated less severity.

WI-NRS is a validated measure of itch severity. Participants were asked daily to rate the intensity of their worst pruritus (itch) over the past 24 hours, using a 11-point scale ranging from 0 (no itch) to 10 (worst imaginable itch). Higher scores indicated more severity.

The IGA CPG-A is an instrument used to assess the overall activity of PN lesions at a given time point, as determined by the investigator. It consists of a 5-point scale ranging from 0 to 4: where 0 = clear (0% nodules showing excoriations/crusts), 1 = almost clear (up to 10% nodules showing excoriations/crusts), 2 = mild (11-25% nodules showing excoriations/crusts), 3 = moderate (26-75% nodules showing excoriations/crusts) and 4 = severe (76-100% of nodules showing excoriations/crusts). Higher scores indicate severe PN.

IGA CPG-S is an instrument used to assess the overall number and thickness of PN lesions at a given time point, as determined by the investigator. It consists of a 5-point scale ranging from 0 to 4 where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe. Higher scores indicate severe PN.

PBI-P is a validated questionnaire where, prior to treatment, individual participants determine how different benefits of therapy would be relevant for them. After treatment, participants will be asked to evaluate the extent to which the benefits they indicated were important to them were, in fact, realized. From all the items taken together, a weighted total benefit value is calculated, which represents the patient relevant therapy benefits. The mean score greater than 1 is considered to represent a clinically relevant improvement. The items are rated on a 5-point scale with values from 0 (not at all) to 4 (very), allowing for 'does/did not apply to me' = 5; and missing value = -9. Higher scores indicate better outcome.

HADS is a 14-item self-administered questionnaire that consists of 2 scales, one measuring anxiety (HADS-A), and the other measuring depression (HADS-D). Each subscale comprised of 7 items with a scoring range from 0 (less severity of anxiety and depression) to 21 (greater severity of anxiety and depression symptoms) for each subscale. The total HADS score ranges from 0 (less severity) to 42 (more severity), with a high score indicative of severe anxiety and/or depression level.

The items of the PAS evaluate the type (visible lesions: item 1a; predominant lesions: item1b), estimated number (item 2), distribution (item 3, 4) and size (biggest lesion: item 6a; representative lesion: item 6b) of pruriginous lesions, the representative body area and exact number of lesions (item 5), the activity in terms of percentage of pruriginous lesions with excoriations/crusts on top (reflecting active scratching; item 7a) and the percentage of healed pruriginous lesions (reflecting healing of CPG; item 7b).